{"id":"https://openalex.org/W2160656155","doi":"https://doi.org/10.1158/1535-7163.mct-09-1071","title":"AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples","display_name":"AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples","publication_year":2010,"publication_date":"2010-03-30","ids":{"openalex":"https://openalex.org/W2160656155","doi":"https://doi.org/10.1158/1535-7163.mct-09-1071","mag":"2160656155","pmid":"https://pubmed.ncbi.nlm.nih.gov/20354122"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-09-1071","doi":"https://doi.org/10.1158/1535-7163.mct-09-1071","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-09-1071","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103324664","display_name":"Matthew S. Squires","orcid":"https://orcid.org/0009-0006-2611-7735","observed_orcids":["https://orcid.org/0009-0006-2611-7735"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Matthew S. Squires","raw_affiliation_strings":["Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111739536","display_name":"Laurence S. Cooke","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Laurence Cooke","raw_affiliation_strings":["Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012124144","display_name":"Victoria Lock","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Victoria Lock","raw_affiliation_strings":["Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039967240","display_name":"Wenqing Qi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wenqing Qi","raw_affiliation_strings":["Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041883762","display_name":"Edward J. Lewis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Jonathan Lewis","raw_affiliation_strings":["Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113528228","display_name":"Neil T. Thompson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neil T. Thompson","raw_affiliation_strings":["Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050224107","display_name":"John F. Lyons","orcid":"https://orcid.org/0009-0002-7080-7937","observed_orcids":["https://orcid.org/0009-0002-7080-7937"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John F. Lyons","raw_affiliation_strings":["Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5035164790","display_name":"Daruka Mahadevan","orcid":"https://orcid.org/0000-0002-2991-0361","observed_orcids":["https://orcid.org/0000-0002-2991-0361"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daruka Mahadevan","raw_affiliation_strings":["Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Astex Therapeutics Ltd., Cambridge, United Kingdom and 2Arizona Cancer Center, Tucson, Arizona","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5103324664"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.5623,"has_fulltext":false,"cited_by_count":56,"citation_normalized_percentile":{"value":0.89143588,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"9","issue":"4","first_page":"920","last_page":"928"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.0026000000070780516,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/at7519","display_name":"AT7519","score":1.0},{"id":"https://openalex.org/keywords/cyclin-dependent-kinase-inhibitors","display_name":"cyclin-dependent kinase inhibitors","score":0.7889999747276306},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9129999876022339},{"id":"https://openalex.org/keywords/b-cell-lymphoproliferative-disorders","display_name":"B-cell lymphoproliferative disorders","score":0.8820000290870667},{"id":"https://openalex.org/keywords/rna-polymerase-ii-phosphorylation","display_name":"RNA polymerase II phosphorylation","score":0.906000018119812},{"id":"https://openalex.org/keywords/transcriptional-inhibition","display_name":"transcriptional inhibition","score":0.8410000205039978},{"id":"https://openalex.org/keywords/mcl-1","display_name":"Mcl-1","score":0.8889999985694885},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.796999990940094},{"id":"https://openalex.org/keywords/poly-adp-ribose-polymerase-cleavage","display_name":"poly(ADP-ribose) polymerase cleavage","score":0.9100000262260437},{"id":"https://openalex.org/keywords/xiap","display_name":"XIAP","score":0.8569999933242798},{"id":"https://openalex.org/keywords/bcl-2","display_name":"Bcl-2","score":0.9929999709129333},{"id":"https://openalex.org/keywords/leukemia-cell-lines","display_name":"leukemia cell lines","score":0.7689999938011169},{"id":"https://openalex.org/keywords/peripheral-blood-mononuclear-cells","display_name":"peripheral blood mononuclear cells","score":0.9629999995231628}],"concepts":[{"id":"https://openalex.org/C33195913","wikidata":"https://www.wikidata.org/wiki/Q20970121","display_name":"XIAP","level":5,"score":0.7766536474227905},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.7389864921569824},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6018157005310059},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.5861148238182068},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.574755847454071},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4995732307434082},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.4859558343887329},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.4683736264705658},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.4531228840351105},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.41241922974586487},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.3664551377296448},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.23831209540367126},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.18726316094398499},{"id":"https://openalex.org/C31573885","wikidata":"https://www.wikidata.org/wiki/Q304484","display_name":"Programmed cell death","level":3,"score":0.13764742016792297},{"id":"https://openalex.org/C98424977","wikidata":"https://www.wikidata.org/wiki/Q25805","display_name":"Caspase","level":4,"score":0.11581066250801086},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.09357911348342896},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.07971784472465515}],"mesh":[{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007938","descriptor_name":"Leukemia","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":true},{"descriptor_ui":"D007938","descriptor_name":"Leukemia","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D007938","descriptor_name":"Leukemia","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D012319","descriptor_name":"RNA Polymerase II","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014158","descriptor_name":"Transcription, Genetic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D016923","descriptor_name":"Cell Death","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D018844","descriptor_name":"Cyclin-Dependent Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051017","descriptor_name":"Apoptosis Regulatory Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.mct-09-1071","doi":"https://doi.org/10.1158/1535-7163.mct-09-1071","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-09-1071","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:20354122","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20354122","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320314605","display_name":"Astex Pharmaceuticals","ror":"https://ror.org/05fx1fs38"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W154103547","https://openalex.org/W297761204","https://openalex.org/W1593333678","https://openalex.org/W1611726375","https://openalex.org/W1980626930","https://openalex.org/W1994898053","https://openalex.org/W2017898416","https://openalex.org/W2029080338","https://openalex.org/W2061249695","https://openalex.org/W2078619764","https://openalex.org/W2080809685","https://openalex.org/W2092042999","https://openalex.org/W2096909009","https://openalex.org/W2124937119","https://openalex.org/W2149658883","https://openalex.org/W2151230965","https://openalex.org/W2153389501","https://openalex.org/W2167292349","https://openalex.org/W3083022941","https://openalex.org/W4211220949"],"related_works":["https://openalex.org/W2535220274","https://openalex.org/W2559834368","https://openalex.org/W2274089490","https://openalex.org/W3106736553","https://openalex.org/W3030439762","https://openalex.org/W2015677689","https://openalex.org/W4385654567","https://openalex.org/W3132914576","https://openalex.org/W2153389501","https://openalex.org/W2138586972"],"abstract_inverted_index":{"AT7519":[0,67,106,179],"is":[1,10],"a":[2,50,181],"potent":[3],"inhibitor":[4],"of":[5,32,47,66,111,121,135,137,146],"several":[6],"cyclin-dependent":[7,18],"kinases":[8,19],"and":[9,22,57,72,74,116,144],"currently":[11],"in":[12,68,78,94,133,162,171],"early":[13],"phase":[14],"clinical":[15],"development.":[16],"Recently,":[17],"7,":[20],"8,":[21],"9":[23],"have":[24],"been":[25],"shown":[26],"to":[27,91,113],"regulate":[28],"transcription":[29],"through":[30],"phosphorylation":[31,136],"RNA":[33,141],"polymerase":[34,142],"II.":[35],"B-cell":[36,188],"lymphoproliferative":[37],"disorders,":[38],"including":[39],"chronic":[40,102],"lymphocytic":[41,103],"leukemia,":[42],"rely":[43],"on":[44,154],"the":[45,64,76,138,147,176],"expression":[46],"transcripts":[48],"with":[49,151,168,186],"short":[51],"half-life,":[52],"such":[53],"as":[54],"Mcl-1,":[55,150],"Bcl-2,":[56],"XIAP,":[58],"for":[59,184],"survival.":[60],"Here,":[61],"we":[62,86],"describe":[63],"characterization":[65],"leukemia":[69,104],"cell":[70,79],"lines,":[71],"compare":[73],"contrast":[75],"response":[77],"lines":[80],"derived":[81],"from":[82,100],"solid":[83],"tumors.":[84],"Finally,":[85],"use":[87],"these":[88],"mechanistic":[89],"insights":[90],"show":[92],"activity":[93],"peripheral":[95],"blood":[96],"mononuclear":[97],"cells":[98],"isolated":[99],"16":[101],"patients.":[105],"induced":[107],"apoptosis":[108],"at":[109],"concentrations":[110],"100":[112],"700":[114],"nmol/L":[115],"was":[117,166],"equally":[118],"effective":[119],"regardless":[120],"Rai":[122],"stage":[123],"or":[124,157],"known":[125],"prognostic":[126],"markers.":[127],"Short-term":[128],"treatments":[129],"(4-6":[130],"hours)":[131],"resulted":[132],"inhibition":[134],"transcriptional":[139],"marker":[140],"II":[143],"downregulation":[145],"antiapoptotic":[148],"protein":[149,164],"no":[152],"effect":[153],"either":[155],"XIAP":[156],"Bcl-2":[158],"levels.":[159],"The":[160],"reduction":[161],"Mcl-1":[163],"level":[165],"associated":[167],"an":[169],"increase":[170],"cleaved":[172],"poly(ADP-ribose)":[173],"polymerase.":[174],"Together":[175],"data":[177],"suggest":[178],"offers":[180],"promising":[182],"treatment":[183],"patients":[185],"advanced":[187],"leukemia.":[189],"Mol":[190],"Cancer":[191],"Ther;":[192],"9(4);":[193],"920-8.":[194],"(c)2010":[195],"AACR.":[196]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":9},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}